VSTM: Verastem Oncology Price-to-Revenue Multiple

Symbol and logo of brand Verastem Oncology (VSTM)

Verastem, Inc. (VSTM) focuses on developing innovative inhibitors to combat solid tumors caused by RAS mutations. The revenue multiple time series on the GURU.Markets chart visualizes the valuation trend, where the 10.60 indicator determines the parameter status. Growth prospects depend on the clinical trial outcomes of drugs targeting lung and ovarian cancers, as well as the implementation of automated screening in laboratories.

VSTM Verastem Corp Market Cap to Revenue (07/04/2022 - 11/13/2026)

Analytical breakdowns for Verastem Inc (VSTM)

- share price and consensus valuation forecast:
Price Performance Chart verastem.com|VSTM - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Verastem Inc|VSTM - Enterprise Value
- book capitalization data:
Net Asset Value per Share Verastem|VSTM - Company Net Assets|Market Cap to Book Value Multiple verastem.com|VSTM - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Verastem, Inc.|VSTM - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Verastem Corp|VSTM - Company Total Debt|Debt to Net Assets Ratio Verastem Inc|VSTM - Company Long-Term Liabilities|Amount of Current Liabilities Verastem|Intermediate Coverage Ratio verastem.com
- earnings and multiples data:
VSTM - Net Profit|Expected Net Profit Verastem, Inc.|VSTM - Price to Earnings Ratio|Future Price to Earnings Multiple Verastem Oncology|VSTM - PEG Multiple|EV/EBITDA Multiple Verastem Inc|VSTM - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Verastem|VSTM - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months verastem.com|VSTM - Net earnings per share growth this year|Net earnings per share growth forecast for next year Verastem, Inc.
- sales revenue and business income indicators:
VSTM - Revenue and Sales Volume|Company Expected Sales Volume verastem.com|VSTM - Price-to-Revenue Ratio|Forward Price to Sales Verastem Inc
Summary company analytics:verastem.com, VSTM
Mass-produced product of verastem.com

Investors are assessing the potential of Verastem, Inc. (VSTM) by analyzing market capitalization relative to revenue, which determines the extent of the premium paid for the biotech's future success. This price-to-sales ratio demonstrates how many dollars an investor pays per unit of actual income, accounting for raw material supply chain disruption risks and patent protection complexities amid geopolitical instability.

Who Verastem, Inc. competes with

GMAB (genmab.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis)|Price-to-Revenue Multiple Nuvalent Inc|Kymera Therapeutics Inc - P/S Multiple|Price to Sales IDEAYA Corp|ELVN (Enliven Therapeutics) - Market Cap to Revenue|ORIC: Market Cap to Sales Volume|RLAY (Relay Therapeutics, Inc.) - P/S Multiple|Price to Sales Nurix Therapeutics Inc NRIX|P/S Multiple TYRA|Monte Rosa Corp - Market Cap to Revenue Ratio|Cullinan Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics, Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX